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Background. Treatment of freezing of gait (FOG) is always challenging because of its unpredictable nature and multifactorial
physiopathology. Intestinal levodopa infusion has been proposed in recent years as a valuable option for its improvement. FOG
in Parkinson’s disease (PD) can appear after deep brain stimulation in patients who never had gait symptoms. Objective. To
study the effects of intestinal levodopa/carbidopa infusion in unresponsive-FOG that appears in PD patients treated with
subthalamic nucleus deep brain stimulation. Methods. We retrospectively collected and analyzed demographic, clinical, and
therapeutic data from five PD patients treated with subthalamic nucleus stimulation who developed unresponsive-FOG and
received intestinal levodopa/carbidopa infusion as an alternative therapy. FOG was measured based on scores in item 14 of the
Unified Parkinson’s Disease Rating Scale before and after intestinal levodopa infusion. Results. Administration of intestinal
levodopa caused improvement of FOG in the “ON” state in four patients (80%) by 2 or more points in item 14 of the Unified
Parkinson’s Disease Rating Scale. ,e improvement was maintained for at least 12 months. Conclusions. Intestinal levodopa
infusion may be a valuable therapeutic option for unresponsive-FOG developed after subthalamic nucleus deep
brain stimulation.
1. Introduction
Freezing of gait (FOG) is defined as short episodes of the
inability to initiate or continue stepping forward and is
typically more evident when turning, facing a narrow space,
or during stress and distraction. Generally, it is related to the
duration and severity of Parkinson’s disease (PD) and is
influenced by sensory and cognitive inputs; however, un-
certainty remains over its ultimate cause [1]. Based on the
response to dopaminergic medication, four types of FOG
have been characterized: OFF-type-FOG, pseudo-ON-FOG,
unresponsive-FOG, and true FOG-ON [2].
Treatment of FOG is a clinical challenge, and different
strategies such as modification of levodopa dosage,
adding catechol-O-methyltransferase inhibitors or
amantadine, deep brain stimulation (DBS), apomorphine,
metilphenidate, and even electroconvulsive therapy have
been used to improve this phenomenon with varying
outcomes [3]. DBS has shown significant improvement in
gait and FOG [4] but in some PD patients can aggravate or
even induce FOG and postural instability [5–7]. Previous
case reports [8, 9] and two recent studies [10, 11] have
found that FOG resistant to conventional oral therapy
may benefit from levodopa/carbidopa intestinal gel
(LCIG) infusion.
Based on this information, we evaluated the effects of
LCIG in unresponsive-FOG with special interest in the ON
state (FOG-ON) that appears de novo after subthalamic
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2. Patients and Methods
Among the 48 PD patients treated with STN-DBS in Bell-
vitge University Hospital (Barcelona, Spain) between 2010
and 2018, 5 patients (P1, P2, P3, P4, and P5) developed
unresponsive-FOG with no previous history of FOG.
FOG is considered “unresponsive” by the presence of
FOG in both the OFF and ON states and is not influenced by
medication [2]. In our study, we considered FOG to be
unresponsive after trying all possible adjustments of DBS
(including switching OFF) and combinations of oral
medication.
,e five patients were selected for treatment with LCIG
as an alternative advanced therapy. DBS was switched OFF
in all patients at least 24 h prior to starting LCIG to better
assess the response to intestinal levodopa infusion. LCIG
infusion via jejunostomy was started according to expert
guidelines, following a nasoduodenal trial.
Demographic, clinical details, DBS state, and charac-
teristics of treatment with LCIG in the five patients were
retrospectively collected (Tables 1 and 2). FOG-ON scores
based on item 14 in the Unified Parkinson’s Disease Rating
Scale (UPDRS) were determined in four treatment condi-
tions: (i) DBS ON and oral medication (ON DBS–ONMed),
(ii) only oral medication (OFF DBS–ON Med), (iii) after 1
month of LCIG treatment, and (iv) after 12 months of LCIG
treatment.
FOG assessment was carried out an hour after the first
morning oral dose of L-Dopa and in daily ON condition
during LCIG infusion.
3. Results
3.1. Patients’ Clinical, Demographic, and DBS Data. In total,
5 of the 48 patients treated with STN-DBS between 2010
and 2018 developed unresponsive-FOG after surgery. All of
the patients were women with a median age of 66 (57–69)
years at the time of surgery, and a median age of 11 (6–12)
years since disease onset. None of them had cognitive
impairment. ,e appearance of FOG was not related to any
surgery complication. ,e median period of time between
surgery and appearance of unresponsive-FOG was 10
(2.5–48) months. P3 suffered an infection in the left
electrode after 2.5 months, but it was correctly replaced and
she remained without gait disturbances until the 10th
month after the first surgery. For P1 and P2, DBS was
switched OFF 2 months before LCIG, and they were only
treated with oral medication because, in addition to the
unresponsive-FOG, STN stimulation did not achieve a fully
satisfactory control of motor fluctuations. To check the
correct positioning of the electrodes within the STN in
these two patients, stereotactic coordinates of the center of
each electrode were referenced to the mid-commissural
point. In P1, the right electrode was 11.5 (X), −3.5 (Y), and
−3.75 (Z), and the left electrode was 11.5 (X), −5 (Y), and
−2.5 (Z). In P2, the right electrode was 13.14 (X), −3.5 (Y),
and −2.15 (Z), and the left electrode was 11.5 (X), −3.58 (Y),
and −2.97 (Z). For P3, P4, and P5, DBS continued ON
bilaterally until 24 h prior to starting LCIG because, despite
FOG, STN-DBS showed significant clinical benefits. ,ese
data are shown in Table 1.
3.2. Characteristics of Treatment with LCIG Infusion and FOG
Data. ,e median age at the beginning of LCIG was 66
(59–71) years, and the median time between surgery and
initiation of LCIG was 18 (8–36) months. Four patients
(80%, P1–P4) had improvement in the FOG-ON with LCIG
equal to or greater than 2 points on item 14 in the UPDRS
scale measured at the first month follow-up. ,e im-
provement was maintained in the four patients for at least 12
months (videos pre/post-LCIG of P1 and P3 are provided).
In P1, P2, and P3, an important improvement in trouble-
some dyskinesias with LCIG was also seen. Subsequently,
two of them (P3 and P4) needed dual therapy (DBS-LCIG)
for better control of the overall PD symptoms. In P5, FOG-
ON did not improve and LCIG was discontinued after 1-
month follow-up, and the patient returned to only DBS ON.
,ese data and the total equivalent doses of levodopa in
each situation are shown in Tables 2 and 3.
4. Discussion
LCIG is available for the treatment of advanced PD with
severe motor fluctuations and dyskinesias that are no longer
controlled by first-line therapies. Since its first use reported
in 1993, LCIG has become a valuable option for advanced
PD control and more indications including nonmotor
symptoms are being studied with promising results [12].
Worsening of gait after DBS has been reported in PD and
non-PD patients [7]. ,is deterioration may happen within
the first days or weeks following DBS surgery and resolve
itself with time (microlesioning effect of the surgery) or after
adjustments in stimulator parameters and oral medication
[13]. However, gait problems may persist in a proportion of
patients regardless of therapy settings [5–7].
In our cohort of 48 PD operated patients between 2010
and 2018, 10% developed unresponsive-FOG de novo.
Buhmann et al. [7] found that about 12% of STN-stimulated
PD patients exhibited nonreversible gait disturbances within
the first 6 months of STN stimulation. ,e cause of this
worsening of gait after DBS is still not fully understood.
Incorrect positioning of the electrodes [14, 15], diffusion of
the stimulatory field to the pedunculopontine nucleus
pathway, or overactivity in STN, which leads to inhibitory
input via internal globus pallidus to the final common
pathway of the brainstem locomotor regions that control
gait [16, 17], are some theories for this deterioration. We
consider the fact that FOG did not improve after a minimum
of 24 h DBS-OFF in any of our patients that it is unlikely that
the gait problems were directly related to stimulation.
It has also been suggested that deterioration in gait is
more likely related to surgery if FOG appears within 6
months after the procedure [7]. In our study, with the ex-
ception of P5, resistant FOG-ON appeared at least 6 months
after surgery.
FOG has always been a challenging symptom in terms of
therapeutic approaches. Chang et al. [8] reported the
2 Parkinson’s Disease
benefits of 24 h LCIG for the treatment of five PD patients
with unresponsive-FOG. In a recent longitudinal study,
Rispoli et al. [11] evaluated the effectiveness of LCIG on
balance and gait, with particular attention being given to
FOG in 15 patients with advanced PD. ,e authors found
significant improvement with LCIG in all patients not re-
lated to overall total equivalent dose of levodopa (LED), but
most likely related to the fine tailoring of LCIG.
Regidor et al. [18] published findings from a study of 19
patients, which suggested that dual therapy (LCIG-DBS)
may be an option for treating advanced PD patients who
develop refractory symptoms after years of acceptable
clinical control with DBS.,ey divided those symptoms into
three groups: axial symptoms measured by the UPDRS axial
subscale, severe pain, and dystonia. ,ey found significant
improvement in the UPDRS axial subscale with DBS-LCIG;
however, they did not specify which item in the axial
subscale improved.
In our patients, one reason for improvement of the un-
responsive-FOG could be related to the tolerance of a higher
LED with LCIG as seen in P3 and P4. ,is is in accordance
with the hypothesis that most FOG during the ON state may
actually be pseudo-ON-FOG and represent patients who are
relatively undertreated, because the “threshold” to improve
FOG is higher than that to improve appendicular motor signs
[19]. However, in P1 and P2, the dose remained almost
unchanged (Table 2). ,erefore, we assume that the benefit is
not only related to a higher LED, but also to the more stable
plasma level that continuous intestinal delivery provides, in
accordance with the study by Rispoli et al. [11].
Table 3: Changes in FOG-ON based on item 14 in the UPDRS scale in the different scenarios.
FOG-ON pre-LCIG
FOG-ON 1st month post-LCIG FOG-ON 12 months post-LCIG
ON DBS–ON Med OFF DBS–ON Med
3 3 1 1
3 3 0 1
4 4 1 1
4 4 2 2
4 4 3 NA
ON DBS–ON Med�DBS ON and oral medication; OFF DBS–ON Med�Only oral medication.



































P1 F 67 11 20 Normal No OFF 3 2
P2 F 69 6 8 Normal No OFF 3 2
P3 F 57 11 10 Normal Infection leftelectrode ON 3 3
P4 F 64 10 48 Normal No ON 2 1
P5 F 66 12 2.5 Normal No ON 3 2
∗Median age (years) at the time of STN-DBS: 66 IQR (57–69). ∗∗Median time (years) from diagnosis to STN-DBS: 11 IQR (6–12). ∗∗∗Median latency
(months) between surgery and unresponsive-FOG onset: 10 IQR (2.5–48). F� female; IQR� interquartile range.























P1 71 2250 2164 2310 OFF 1 1
P2 70 2400 2130 1960 OFF 1 1
P3 59 855 1233 1098 ON 1 1
P4 70 885 1638 1914 ON 1 1
P5 66 1874 2100 NA ON NA NA
∗Median age (years) at the time of LCIG: 66 IQR (59–71). ∗∗Median LED (mg) pre-LCIG: 1874 IQR (855–2400). ∗∗∗Median LED (mg) post-LCIG after 1
month: 2100 IQR (1233–2164). ∗∗∗∗Median LED (mg) post-LCIG after 12 months: 1937 IQR (1098–2310). LED pre-LCIG� total equivalent dose of levodopa
oral medication; LED post-LCIG� total equivalent dose of levodopa after LCIG (LCIG plus oral control release); NA�not applicable; IQR� interquartile
range.
Parkinson’s Disease 3
To note, LCIG helped control troublesome dyskinesias in
P1, P2, and P3. One may also hypothesize that troublesome
dyskinesia played a role in the poor gait performance [20].
,e study has limitations including a small sample size,
the fact data was collected retrospectively, and that FOG was
only measured using the UPDRS item 14. ,e relatively short
follow-up may also be considered a limitation because,
according to a recently published study [21], control over axial
symptoms seems to diminish after 4 years of initiating LCIG.
5. Conclusions
LCIG might be a valuable therapeutic option for unre-
sponsive-FOG after STN-DBS. ,e improvement of FOG-
ON and overall satisfaction of our patients after LCIG were
notable. ,erefore, future larger trials should be conducted
to confirm these findings.
Data Availability
,e study data are available on request to the corresponding
author.
Additional Points
Highlights. Freezing of gait in Parkinson’s disease can appear
after deep brain stimulation. Treatment of freezing of gait is
challenging. Intestinal levodopa/carbidopa could be a
therapeutic option in this situation.,e improvement might
be related with higher dose and more stable plasma levels
with intestinal levodopa/carbidopa.
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Supplementary Materials
Video 1 (P1 pre-LCIG): freezing of gait in the ON state in
patient 1 before treatment with levodopa/carbidopa in-
testinal gel. ,is clip shows patient 1 in a wheelchair having
difficulties standing up and not being able to walk. DBS was
OFF when the video was recorded. Video 2 (P1 post-LCIG):
freezing of gait in the ON state in patient 1 after treatment
with levodopa/carbidopa intestinal gel. ,is clip shows the
improvement in FOG-ON after treatment with levodopa/
carbidopa gel. ,e patient stands up at first attempt and
demonstrates mild freezing when beginning to walk and
turning. DBS was OFF when the video was recorded. Video
3 (P3 pre-LCIG): freezing of gait in the ON state in patient 3
before treatment with levodopa/carbidopa intestinal gel.
,is clip shows patient 3 being unable to rise from the chair
and walk without assistance. Severe freezing and gener-
alised dyskinesias are shown. DBS was OFF when the video
was recorded. Video 4 (P3 post-LCIG): freezing of gait in
the ON state in patient 3 after treatment with levodopa/
carbidopa intestinal gel. ,is clip shows the improvement
in FOG-ON after treatment with levodopa/carbidopa gel.
,e patient is able to rise from the chair with arms-crossed
and walks independently with only mild freezing when
beginning to walk and turning. DBS was OFF when the
video was recorded. (Supplementary Materials)
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